proteome and a $4 million pre-seed funding round. A 2024 graduate of SOSV’s IndieBio SF, Rybodyn is targeting the dark proteome to pioneer first-in-class immunotherapies for cancer – with the potential to address a wide range of other diseases as well.
Proton Intelligence has raised a $6.95M seed round to accelerate their work on a continuous potassium monitor that aims revolutionize clinical care for at risk patients. Participants in the round included SOSV, We Venture Capital (Werfen), Tenmile, LongeVC, 15th Rock, Exor, and Trampoline Venture Partners.
Unibaio wins the $1M grand prize in ESD’s Grow-NY International Food and Agriculture Business Competition
OneSkin closes $7M Series A, accelerating their groundbreaking efforts in skin health and longevity
